211 related articles for article (PubMed ID: 17511440)
21. Design, Synthesis, and Biological Activity of Isosyringolin A.
Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
[TBL] [Abstract][Full Text] [Related]
22. Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells.
Archer CR; Groll M; Stein ML; Schellenberg B; Clerc J; Kaiser M; Kondratyuk TP; Pezzuto JM; Dudler R; Bachmann AS
Biochemistry; 2012 Aug; 51(34):6880-8. PubMed ID: 22870914
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates.
Zhu Y; Zhao X; Zhu X; Wu G; Li Y; Ma Y; Yuan Y; Yang J; Hu Y; Ai L; Gao Q
J Med Chem; 2009 Jul; 52(14):4192-9. PubMed ID: 19537716
[TBL] [Abstract][Full Text] [Related]
24. New cyclic peptide proteasome inhibitors.
Baldisserotto A; Marastoni M; Gavioli R; Tomatis R
Bioorg Med Chem Lett; 2009 Apr; 19(7):1966-9. PubMed ID: 19250821
[TBL] [Abstract][Full Text] [Related]
25. N-methylsansalvamide a peptide analogues. Potent new antitumor agents.
Liu S; Gu W; Lo D; Ding XZ; Ujiki M; Adrian TE; Soff GA; Silverman RB
J Med Chem; 2005 May; 48(10):3630-8. PubMed ID: 15887970
[TBL] [Abstract][Full Text] [Related]
26. Simplified synthetic TMC-95A/B analogues retain the potency of proteasome inhibitory activity.
Yang ZQ; Kwok BH; Lin S; Koldobskiy MA; Crews CM; Danishefsky SJ
Chembiochem; 2003 Jun; 4(6):508-13. PubMed ID: 12794861
[TBL] [Abstract][Full Text] [Related]
27. Design, Synthesis and Biological Evaluation of a Structurally Simplified Syringolin A Analogues.
Chiba T; Kitahata S; Matsuda A; Ichikawa S
Chem Pharm Bull (Tokyo); 2016; 64(7):811-6. PubMed ID: 27373636
[TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationship study of syringolin A as a potential anticancer agent.
Chiba T; Matsuda A; Ichikawa S
Bioorg Med Chem Lett; 2015 Nov; 25(21):4872-4877. PubMed ID: 26231162
[TBL] [Abstract][Full Text] [Related]
29. The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity.
Clerc J; Li N; Krahn D; Groll M; Bachmann AS; Florea BI; Overkleeft HS; Kaiser M
Chem Commun (Camb); 2011 Jan; 47(1):385-7. PubMed ID: 20830349
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
Itoh Y; Suzuki T; Kouketsu A; Suzuki N; Maeda S; Yoshida M; Nakagawa H; Miyata N
J Med Chem; 2007 Nov; 50(22):5425-38. PubMed ID: 17929798
[TBL] [Abstract][Full Text] [Related]
31. Total synthesis and antitubulin activity of c10 analogues of cryptophycin-24.
Buck SB; Huff JK; Himes RH; Georg GI
J Med Chem; 2004 Jan; 47(3):696-702. PubMed ID: 14736249
[TBL] [Abstract][Full Text] [Related]
32. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
Dorsey BD; Iqbal M; Chatterjee S; Menta E; Bernardini R; Bernareggi A; Cassarà PG; D'Arasmo G; Ferretti E; De Munari S; Oliva A; Pezzoni G; Allievi C; Strepponi I; Ruggeri B; Ator MA; Williams M; Mallamo JP
J Med Chem; 2008 Feb; 51(4):1068-72. PubMed ID: 18247547
[TBL] [Abstract][Full Text] [Related]
33. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
[TBL] [Abstract][Full Text] [Related]
34. Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
Rydzewski RM; Burrill L; Mendonca R; Palmer JT; Rice M; Tahilramani R; Bass KE; Leung L; Gjerstad E; Janc JW; Pan L
J Med Chem; 2006 May; 49(10):2953-68. PubMed ID: 16686537
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, in vitro and in vivo biological evaluation, and comprehensive understanding of structure-activity relationships of dipeptidyl boronic acid proteasome inhibitors constructed from β-amino acids.
Zhu Y; Wu G; Zhu X; Ma Y; Zhao X; Li Y; Yuan Y; Yang J; Yu S; Shao F; Lei M
J Med Chem; 2010 Dec; 53(24):8619-26. PubMed ID: 21077681
[TBL] [Abstract][Full Text] [Related]
36. New antitumour cyclic astin analogues: synthesis, conformation and bioactivity.
Rossi F; Zanotti G; Saviano M; Iacovino R; Palladino P; Saviano G; Amodeo P; Tancredi T; Laccetti P; Corbier C; Benedetti E
J Pept Sci; 2004 Feb; 10(2):92-102. PubMed ID: 14994987
[TBL] [Abstract][Full Text] [Related]
37. N-terminal-prolonged vinyl ester-based peptides as selective proteasome beta1 subunit inhibitors.
Baldisserotto A; Destro F; Vertuani G; Marastoni M; Gavioli R; Tomatis R
Bioorg Med Chem; 2009 Aug; 17(15):5535-40. PubMed ID: 19577931
[TBL] [Abstract][Full Text] [Related]
38. Peptidyl vinyl ester derivatives: new class of selective inhibitors of proteasome trypsin-like activity.
Marastoni M; Baldisserotto A; Cellini S; Gavioli R; Tomatis R
J Med Chem; 2005 Jul; 48(15):5038-42. PubMed ID: 16033282
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and in vitro antitumor activity of new 1,4-diarylimidazole-2-ones and their 2-thione analogues.
Congiu C; Cocco MT; Onnis V
Bioorg Med Chem Lett; 2008 Feb; 18(3):989-93. PubMed ID: 18164978
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, radiosynthesis, and biological evaluation of new proteasome inhibitors in a tumor targeting approach.
Vivier M; Rapp M; Papon J; Labarre P; Galmier MJ; Sauzière J; Madelmont JC
J Med Chem; 2008 Feb; 51(4):1043-7. PubMed ID: 18237109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
